Вряд ли речь о преимуществе. [
Ссылки доступны только зарегистрированным пользователям ]
Цитата:
|
Clinical benefit (CB) was first successfully used as an endpoint in 1997 in the pivotal study of gemcitabine in advanced pancreas cancer. In the trial by Burris et al (J Clin Oncol. 1997) CB was a composite measure of pain, performance status, and weight. Here we describe how CB has been used in oncology trials since that time
|
[
Ссылки доступны только зарегистрированным пользователям ]
Цитата:
|
The term “clinical benefit” can be interpreted in a number of ways but is commonly accepted to mean that the agent demonstrates an improvement in survival compared with no therapy or to a known effective therapy, equivalence or noninferiority to a known effective treatment, or, in some cases, a clear improvement in time to disease progression together with an improvement in symptoms or QoL3 for the patient
|
Довольно обширное понятие, но определяющее все же позитивную динамику процесса, улучшение. ИМХО.
[
Ссылки доступны только зарегистрированным пользователям ]